Richmond Pharmacology

Thank You for Making a Difference! 🙏

Our hashtag was a huge success, thanks to everyone who participated! Staff and local workers from around London Bridge joined for free CPR training, led by our expert team.

Eddie Wilkins, a taxi driver for London Airport Taxis, said: "The session was very informative and hands-on. I feel confident now that if someone falls unconscious while in my cab, I will know what to do until an ambulance arrives."

Stay tuned for more impactful events!

Interested in working for the UK's leading CRO? Want to do quality research with some of the industry's best? We are recruiting! Take a look at some of the roles available here workatrichmondpharmacology.co.uk/vacancies

A new competitive prostaglandin-F receptor (FP) antagonist with myometrial selectivity is being developed to reduce uterine contractions during pre-term labour. We carried out the first-in-human study of this therapy, also known as OBE002 to understand its effect on cardiac repolarization.

Take a look at the full study here: assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4e845aa4f64df99cbf473d_OBE022%20(1).pdf

Accelerating drug development timelines; how do we do it? Watch the video to find out www.youtube.com/watch?v=m0uay9AJ5Gg

Our database of active Japanese study volunteers has now reached over 20,000!

The database has expanded by 20 times in the last 10 years, and is full of people ready to engage in a study. To find out more information about our patient and volunteer recruitment capabilities, click here www.richmondpharmacology.com/specialist-services/patient-recruitment

Food ingestion in healthy volunteers leads to an increase in heart rate cardiac stroke volume. When someone consumes a meal, an ECG shows QTc interval shorterning from a fasting baseline up to 7 hours.

Prior observations indicate that calcium block primarily affects early repolarization by shortening the J-T peak c interval. Take a look at our study into the influence of calcium blockade on the QT effects of a meal here: assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4e80367719ad0597722d94_Calcium-blockade-ACCP-Poster-1-WEB.pdf

People with Type 1 Diabetes are often at higher risk of experiencing heart attacks. This disproportionate outcome is concerning, but why does it happen? It could be to do with the effect of high blood sugar on the heart. To understand this occurrence further, we studied the impact of Hyperglycemia on the heart. Read more here assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4e76de19eeb20a2e2b2d53_hERG-blocking-agents-portrait-WEB.pdf

Today is 2023, and our staff are wearing red to support and raise awareness about clinical research. Our colleagues across the industry working in clinical roles, study participants and regulatory bodies are the powerhouses behind bringing better outcomes to patients.

brings together all parties that support and undertake research. On the front line and behind the scenes, incredible research teams collectively work on health and social care research. For more information, click here https://rdforum.nhs.uk/red4research-2023/

Many people globally suffer from acid-related disorders such as acid reflux. TAK-438 (or Vanoprazan) is a small molecule, oral potassium-competitive acid blocker that helps suppress gastric acid.

Read more about our study into this drug - which has since received a license to go to market - here: https://ow.ly/MeCw50OLEpm

Our Associate Training and Education Manager, Lucy Sze says she feels "extremely fortunate to be part of a dynamic and highly motivated team.' Since she joined us three years ago, there have been "many challenging milestones, but the resilience to overcome hardships and come out the other side, provides me with personal/professional leadership experience and motivation to succeed." Read more about Lucy and the rest of our colleagues here workatrichmondpharmacology.co.uk/our-people

Our People Here are some of the people you’ll be working alongside if you join our team.

It is widely documented in the literature that the consumption of cruciferous vegetables can suppress the initial phase of carcinogenesis or the progression of neoplastic cells to cancer. This may be because of Sulforaphane, a derivative of glucoraphanin. Read more about our Phase 1 study involving a promising non-cytotoxic anti-cancer agent, Sulforadex.

https://assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4eccd2f48d1e1ca0dfe41c_Evgen-BPS-poster-tiny-web.pdf

assets.website-files.com